Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,745 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Are skin tests useful in fluoroquinolone hypersensitivity diagnosis?
Perez E, Callero A, Martinez-Tadeo JA, Hernandez G, Rodríguez-Plata E, Almeida Z, Garcia-Robaina JC. Perez E, et al. Ann Allergy Asthma Immunol. 2013 Nov;111(5):423-5. doi: 10.1016/j.anai.2013.08.012. Epub 2013 Sep 12. Ann Allergy Asthma Immunol. 2013. PMID: 24125154 No abstract available.
A case report of allergy to exenatide.
Pérez E, Martínez-Tadeo J, Callero A, Hernández G, Rodríguez-Plata E, García-Robaina JC. Pérez E, et al. J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):822-3. doi: 10.1016/j.jaip.2014.05.011. Epub 2014 Jul 25. J Allergy Clin Immunol Pract. 2014. PMID: 25439386 No abstract available.
Detemir insulin-induced anaphylaxis.
Pérez E, González R, Martínez J, Iglesias J, Matheu V. Pérez E, et al. Ann Allergy Asthma Immunol. 2009 Feb;102(2):174-5. doi: 10.1016/S1081-1206(10)60255-4. Ann Allergy Asthma Immunol. 2009. PMID: 19230476 No abstract available.
Omalizumab for drug allergy.
Matheu V, Franco A, Perez E, Hernández M, Barrios Y. Matheu V, et al. Among authors: perez e. J Allergy Clin Immunol. 2007 Dec;120(6):1471-2; author reply 1472-3. doi: 10.1016/j.jaci.2007.07.037. Epub 2007 Sep 12. J Allergy Clin Immunol. 2007. PMID: 17854881 No abstract available.
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
Mezzanotte-Sharpe J, ONeill A, Mayer IA, Arteaga CL, Yang XJ, Wagner LI, Cella D, Meropol NJ, Alpaugh RK, Saphner TJ, Swaney RE, Hoelzer KL, Gradishar WJ, Abramson VG, Sundaram PK, Jilani SZ, Perez EA, Lin NU, Jahanzeb M, Wolff AC, Sledge GW, Reid SA. Mezzanotte-Sharpe J, et al. Among authors: perez ea. Res Sq [Preprint]. 2024 Apr 29:rs.3.rs-4295044. doi: 10.21203/rs.3.rs-4295044/v1. Res Sq. 2024. PMID: 38746356 Free PMC article. Preprint.
2,745 results